Impact Of Thyroid Dysfunction on Liver Function Tests

January 20, 2026 updated by: Omnia Ahmed Mohamed Aref, Sohag University

Impact Of Thyroid Dysfunction on Liver Function Tests In Sohag University Hospital

This study aims to evaluate the effect of thyroid dysfunction on liver function tests.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Usama M Abdel-Aal, Professor

Study Locations

  • Egypt
      • Sohag, Egypt
        • Recruiting
        • Sohag university Hospital
        • Contact:
          • Magdy M Amin, Professor
          • Phone Number: 01090801900

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

All patients between the ages of 20-60 years old either with Hypothyroidism or Hyperthyroidism (controlled on treatment or not) and firstly diagnosed Hypothyroidism or Hyperthyroidism.

Description

Inclusion Criteria:

  • All patients between the ages of 20-60 years old either with Hypothyroidism or Hyperthyroidism (controlled on treatment or not) and firstly diagnosed Hypothyroidism or Hyperthyroidism.
  • Euthyroid controls (clinically healthy control subjects were recruited from the general population with the same socio-economic status with the subjects.)

Exclusion Criteria:

  • Patients aged < 20 years old.
  • Patients With Liver Disease.
  • Pregnant and lactating women.
  • Patients with severe infections or sepsis.
  • Patients with Heart Disease.
  • Patients who on drugs that can affect liver function such as phenothiazine, phenylbutazone, methyldopa, among others.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control group
Other: Control group
Healthy people
Patients with hypothyroidism or hyperthyroidism that are controlled on treatment
Other: Patients with hypothyroidism or hyperthyroidism that are controlled on treatment
This group includes patients with hypothyroidism or hyperthyroidism that are controlled on treatment
Patients with hypothyroidism or hyperthyroidism that are not controlled on treatment
Other: Patients with hypothyroidism or hyperthyroidism that are not controlled on treatment
This group includes patients with hypothyroidism or hyperthyroidism that are not controlled on treatment
Patients with hypothyroidism or hyperthyroidism that are firstly discovered
Other: Patients with hypothyroidism or hyperthyroidism that are firstly discovered
This group includes patients with hypothyroidism or hyperthyroidism that are firstly discovered

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measuring total bilirubin level in patients with thyroid dysfunction diseases
Time Frame: 1 months
Collecting blood samples from the patients
1 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 14, 2025

Primary Completion (Estimated)

January 30, 2026

Study Completion (Estimated)

January 30, 2026

Study Registration Dates

First Submitted

September 30, 2025

First Submitted That Met QC Criteria

January 20, 2026

First Posted (Actual)

January 21, 2026

Study Record Updates

Last Update Posted (Actual)

January 21, 2026

Last Update Submitted That Met QC Criteria

January 20, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med--25-7-9MS

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thyroid Disease

Clinical Trials on Control group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe